Develops Allocetra, a macrophage reprogramming cell therapy for knee osteoarthritis and other inflammatory and degenerative conditions, and intends to earn from regulatory approval, commercialization or out-licensing of that candidate, while holding a prediction-markets digital asset treasury alongside the clinical programme.
